Navigation Links
AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
Date:10/19/2009

QUEBEC CITY, Oct. 19 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it has initiated activities intended to complete the clinical development of the growth hormone secretagogue (GHS) / ghrelin agonist compound macimorelin (AEZS-130) which could be the first oral diagnostic test approved for growth hormone deficiency (GHD). Macimorelin is the International Non-proprietary Name (INN) designated for the compound by the World Health Organization (WHO).

AEterna Zentaris has already assumed the sponsorship of the Investigational New Drug application (IND) and is discussing with the FDA the best way to complete the ongoing Phase 3 clinical trial, and subsequently file a New Drug Application (NDA) for approval of macimorelin (AEZS-130) as a diagnostic test for GHD in adults.

The Phase 3 clinical trial of macimorelin (AEZS-130), to establish it as a diagnostic test for GHD in adults, was initiated in the USA by AEterna Zentaris' former licensee, Ardana Biosciences Ltd. (Ardana); however, the trial was suspended before completion because of Ardana's insolvency. Additionally, AEterna Zentaris regained all rights and acquired all assets related to macimorelin (AEZS-130) as a result of the insolvency process.

The pivotal Phase 3 trial (listed in clinicaltrials.gov, study #NCT00448747) is designed to investigate the safety and efficacy of the oral administration of macimorelin (AEZS-130) as a growth hormone stimulation diagnostic test compared to GHRH + L-arginine, administered intravenously. Currently available results from this study, previously reported by G. Merriam et al. (Poster P2-749, ENDO '09, June 2009), demonstrated no safety issues and better discrimination between adult GHD patie
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2015)... The 2015 Market Research Report ... professional and in-depth study on the current state ... with a focus on the Chinese situation. Major ... are Linde Industrial Gas, Basf, Air Products, Air ... Group, Longsheng Group, Juhua Group, Wandali Gas, Unid(Jiangsu) ...
(Date:5/22/2015)... 2015 According to a new ... 2D Gel Electrophoresis, Agarose & Polyacrylamide Gel, Capillary Electrophoresis, ... Application & by End User - Global Forecast to ... to reach around $1.98 Billion by 2020 with a ... 2020. Browse 226 ma rket ...
(Date:5/22/2015)... Baylor Research Institute (BRI) at Dallas ... in Phoenix, AZ , today announce an ... for patients with a broad range of cancers. Aligning the ... trials and access to technology to drive the development of ... across Baylor Scott & White Health,s 49 hospitals ...
(Date:5/21/2015)... 21, 2015 Specialty Pharmacy Times ... been admitted to BPA Worldwide as a business ... track audience data for Specialty Pharmacy Times based ... “By becoming a member of BPA Worldwide, Specialty ... our clients with the most reliable, unequaled data,” ...
Breaking Biology Technology:Global Hydrogen Chloride Industry 2015 Trends and Analysis Available in a New Report at DeepResearchReports.com 2Global Hydrogen Chloride Industry 2015 Trends and Analysis Available in a New Report at DeepResearchReports.com 3Electrophoresis Market Worth $1.98 Billion by 2020 2Electrophoresis Market Worth $1.98 Billion by 2020 3Electrophoresis Market Worth $1.98 Billion by 2020 4Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4Specialty Pharmacy Times Joins BPA Worldwide 2
... Vaccine Indicated to Prevent, Rotavirus Caused by ... of the Vaccination by Four Months of Age, with ... 20 ,GlaxoSmithKline (NYSE: GSK ) announced today that ... Biological Products Advisory,Committee (VRBPAC) provided a favorable recommendation for ...
... Cadence Pharmaceuticals,Inc. (Nasdaq: CADX ), a ... product candidates principally,for use in the hospital setting, ... direct offering of approximately 9.2,million shares of common ... for gross,proceeds of $49.3 million., "The proceeds ...
... been miniaturized to take up less space and weigh ... conversion electronics on the James Webb Space Telescope being ... analog signals to digital signals and provide better images ... have been miniaturized from a volume of about one ...
Cached Biology Technology:GSK Receives Favorable Recommendation by FDA Advisory Committee for Rotarix(R) (Rotavirus Vaccine, Live, Oral) 2GSK Receives Favorable Recommendation by FDA Advisory Committee for Rotarix(R) (Rotavirus Vaccine, Live, Oral) 3GSK Receives Favorable Recommendation by FDA Advisory Committee for Rotarix(R) (Rotavirus Vaccine, Live, Oral) 4Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering 2Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering 3Amazing minaturized 'SIDECAR' drives Webb telescope's signal 2Amazing minaturized 'SIDECAR' drives Webb telescope's signal 3
(Date:5/14/2015)... Research and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) ... Market in Smart Mobile Devices " report to ... was a watershed year for fingerprint sensors in smartphones ... Apple gave fingerprint sensors a raison d,etre in the ... are a must-have feature in flagship smartphones. ...
(Date:5/11/2015)... RYE, N.Y. , May 11, 2015 ... company, announced the start of a new Phase III ... effect of its novel formulation, CM-AT, on all children ... results of its FDA Phase III double blinded clinical ... who had low levels of the digestive enzyme chymotrypsin. ...
(Date:5/6/2015)... , May 6, 2015 LifeBEAM, a developer ... helmet producer, announced today that they will expand their ... world,s first bio-sensing cycling helmet and the first joint ... two new colors in order to give cyclists more ... In addition, LifeBEAM and Lazer announced their plan to ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... for the meeting Experimental Biology 2010 the American ... Society for Biochemistry and Molecular Biology, American Society ... American Society for Pharmacology and Experimental Therapeutics are ... presented April 24-28, at the Anaheim Convention Center. ...
... April 12, 2010) -- The U.S. Environmental ... hold its 2010 Decontamination Research and Development Conference ... Airport Hotel in North Carolina. This year,s ... and outdoor areas and of materials contaminated with ...
... a key factor that is often overlooked in discussions ... in the International Journal of Agricultural Resources, Governance ... footprints, water resources and climate change. However, the non-renewable ... the global context. Biologist John Lott of McMaster ...
Cached Biology News:Selected highlights of the research being presented at the Experimental Biology 2010 meeting 2Selected highlights of the research being presented at the Experimental Biology 2010 meeting 3Selected highlights of the research being presented at the Experimental Biology 2010 meeting 4Calculating agriculture's phosphorus footprint 2
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
Alkali soluble casein is the recommended blot blocking reagent for use with the HisTag Monoclonal Antibody (Novagen) on Western blots....
Ephrin A4...
Formulation: 10mM PBS/500 mM NaCl, 0.09% NaN3, pH 7.2...
Biology Products: